Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMOKN27)

Drug Name
AM-281 Drug Info
Synonyms
AM 281; 202463-68-1; AM281; AM-281; UNII-SBP4A4DYH2; SBP4A4DYH2; 1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-morpholinyl-1H-pyrazole-3-carboxamide; CHEMBL476833; 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-morpholin-4-ylpyrazole-3-carboxamide; 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-morpholino-1H-pyrazole-3-carboxamide; Tocris-1115; AC1N7ICF; GTPL741; SCHEMBL1517458; CTK8E9266; CHEBI:93039; AJFFBPZYXRNAIC-UHFFFAOYSA-N; MolPort-003-940-033; HMS3267K18; EX-A1546; ZINC2575699; BCP07951; BN0064
Cross-matching ID
PubChem CID
4302962
ChEBI ID
CHEMBL476833
CAS Number
CAS 202463-68-1
TTD Drug ID
D0UD9H

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Staphylococcus aureus infection 1.90 5.16e-2 72/95 (75.79%) KRT17;KRT14;KRT23;...
Glycosaminoglycan biosynthesis 1.66 3.57e-1 40/58 (68.97%) EXT1;CHST15;B4GALT4;...
Asthma 1.66 2.44e-1 25/31 (80.65%) CD40;HLA-DQA1;HLA-DPA1;...
Protein export 1.62 2.64e-1 17/23 (73.91%) OXA1L;SEC11A;HSPA5;...
Intestinal immune network for IgA production 1.56 3.35e-1 38/48 (79.17%) IL6;CD40;HLA-DQA1;...
Pentose phosphate pathway 1.55 3.02e-1 25/30 (83.33%) RBKS;PGM1;G6PD;...
Oxidative phosphorylation 1.54 2.81e-1 93/133 (69.92%) ATP6V1D;ATP5F1D;NDUFB5;...
IL-17 signaling pathway 1.52 3.00e-1 84/94 (89.36%) S100A7;S100A9;MUC5B;...
Nicotine addiction 1.51 2.81e-1 32/40 (80%) GABRP;SLC17A6;GABRA1;...
Protein processing in endoplasmic reticulum 1.44 4.44e-1 127/171 (74.27%) HERPUD1;CAPN2;HSP90B1;...
Cardiac muscle contraction 1.44 4.06e-1 64/87 (73.56%) TPM4;ATP1A1;ATP1A2;...
Bile secretion 1.43 4.25e-1 68/90 (75.56%) CA2;GNAS;ATP1A1;...
Complement and coagulation cascades 1.42 4.12e-1 76/85 (89.41%) SERPINA1;PLAT;CFB;...
Regulation of lipolysis in adipocytes 1.40 4.30e-1 52/55 (94.55%) NPY1R;IRS1;MGLL;...
Starch and sucrose metabolism 1.38 4.96e-1 25/36 (69.44%) PYGL;MGAM;PGM1;...
Legionellosis 1.37 4.84e-1 51/57 (89.47%) CYCS;IL6;CXCL1;...
Estrogen signaling pathway 1.37 4.70e-1 119/137 (86.86%) KRT17;KRT14;KRT23;...
Pathogenic Escherichia coli infection 1.36 4.75e-1 152/197 (77.16%) TUBB2A;MYH10;CYCS;...
Base excision repair 1.35 4.66e-1 29/33 (87.88%) POLE2;NEIL3;PCNA;...
Nucleotide excision repair 1.32 5.57e-1 40/47 (85.11%) POLE2;RFC2;CUL4A;...
Steroid biosynthesis 1.32 5.51e-1 19/20 (95%) NSDHL;MSMO1;CYP27B1;...
Caffeine metabolism 1.31 5.34e-1 5/6 (83.33%) NAT1;CYP2A6;CYP1A2
Neutrophil extracellular trap formation 1.30 5.54e-1 101/189 (53.44%) NCF2;CYBA;FGA;...
DNA replication 1.30 5.36e-1 34/36 (94.44%) POLE2;RFC2;RNASEH2A;...
Regulation of actin cytoskeleton 1.30 5.28e-1 185/218 (84.86%) PDGFC;MYH10;ITGA2;...
Bacterial invasion of epithelial cells 1.28 5.71e-1 59/77 (76.62%) CDC42;ARPC3;MET;...
Diabetic cardiomyopathy 1.28 5.76e-1 162/203 (79.8%) IRS1;COL3A1;COL1A2;...
Salmonella infection 1.26 6.06e-1 198/249 (79.52%) AHNAK;TUBB2A;CYCS;...
Proximal tubule bicarbonate reclamation 1.24 6.51e-1 21/23 (91.3%) CA2;ATP1A1;ATP1A2;...
Tight junction 1.17 6.54e-1 130/169 (76.92%) MYH10;CDC42;ERBB2;...
Wnt signaling pathway -1.22 3.82e-1 124/166 (74.7%) CTBP1;EP300;FRAT2;...
GnRH secretion -1.23 3.79e-1 60/64 (93.75%) GPER1;PLCB3;GNA11;...
Hepatocellular carcinoma -1.24 3.76e-1 135/168 (80.36%) KEAP1;PTEN;PRKCB;...
Glyoxylate and dicarboxylate metabolism -1.24 3.77e-1 23/30 (76.67%) DLD;GLDC;GLUL
Insulin signaling pathway -1.24 3.76e-1 121/137 (88.32%) LIPE;MAPK9;PDE3B;...
Lysosome -1.25 3.76e-1 115/128 (89.84%) LAMP2;TCIRG1;ARSB;...
Linoleic acid metabolism -1.25 3.81e-1 21/29 (72.41%) CYP3A4;PLA2G6;CYP2E1;...
Aldosterone synthesis and secretion -1.25 3.75e-1 85/98 (86.73%) PLCB3;NR4A1;CYP11A1;...
Glycolysis / Gluconeogenesis -1.25 3.79e-1 56/67 (83.58%) ALDH3A1;PFKL;ENO1;...
Cushing syndrome -1.26 3.81e-1 125/155 (80.65%) AIP;ARNT;PLCB3;...
Histidine metabolism -1.29 3.68e-1 16/22 (72.73%) ALDH7A1;HDC;MAOA;...
Peroxisome -1.30 3.76e-1 72/82 (87.8%) SOD1;DECR2;MVK;...
Autophagy -1.30 3.80e-1 113/169 (66.86%) ATG4B;DAPK3;STK11;...
Prolactin signaling pathway -1.31 3.67e-1 66/70 (94.29%) PIK3R2;STAT5A;MAPK10;...
Glucagon signaling pathway -1.31 3.70e-1 89/107 (83.18%) PFKL;PRKAG2;PLCB3;...
Circadian entrainment -1.31 3.77e-1 85/97 (87.63%) PLCB4;GNB2;GUCY1B1;...
AMPK signaling pathway -1.32 3.68e-1 106/120 (88.33%) PFKM;PDPK1;RAB14;...
Phosphatidylinositol signaling system -1.32 3.73e-1 82/97 (84.54%) DGKB;IMPA1;DGKQ;...
Arginine biosynthesis -1.36 3.62e-1 17/22 (77.27%) GLS;GLUD2;GLUD1;...
Arachidonic acid metabolism -1.36 3.72e-1 48/61 (78.69%) GGT1;PLA2G4A;ALOX5;...
Pancreatic secretion -1.37 3.63e-1 87/102 (85.29%) PLCB3;KCNQ1;PNLIP;...
Pantothenate and CoA biosynthesis -1.38 3.54e-1 14/21 (66.67%) COASY;AASDHPPT;BCAT1;...
Selenocompound metabolism -1.38 3.69e-1 11/17 (64.71%) CTH;SEPHS2;TXNRD1;...
Proteasome -1.58 2.31e-1 44/46 (95.65%) PSMD2;PSMB6;PSMB9;...
Ubiquinone and other terpenoid-quinone biosynthesis -1.59 2.51e-1 9/11 (81.82%) COQ6;VKORC1;COQ3;...
Fat digestion and absorption -1.61 2.45e-1 35/43 (81.4%) PNLIPRP1;APOA4;PLA2G1B;...
Sphingolipid metabolism -1.71 1.08e-1 32/49 (65.31%) CERS6;SGPP1;GALC;...
Metabolism of xenobiotics by cytochrome P450 -1.72 1.24e-1 49/77 (63.64%) AKR7A3;CBR1;CYP2D6;...
Ferroptosis -1.74 1.52e-1 36/41 (87.8%) SLC7A11;ATG5;SLC11A2;...
Tyrosine metabolism -1.87 1.05e-1 30/36 (83.33%) FAH;PNMT;COMT;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H, 24H
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H, 24H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H